More than three decades after the Australian Medical Association first raised concerns about the possible toxicity of astraggalus, the industry is now seeking to continue with its business despite mounting evidence of potential risks.

The AAMC has warned the Government that the Australian Government is subsidizing the production and sale of anastragalgas-derived products, including anastrakides.

The Pharmaceutical Benefits Scheme (PBS) is a $25 billion-a-year insurance program designed to help Australians afford cancer treatment. AAP/ABC